CSL Behring Launches MySource™ at the National Hemophilia Foundation's 65th Annual Meeting

 CSL Behring Launches MySource™ at the National Hemophilia Foundation's 65th
                                Annual Meeting

MySource Offers One-Stop Access to Information About CSL Behring's Innovative
Patient-Support Offerings

PR Newswire

ANAHEIM, Calif., Oct. 3, 2013

ANAHEIM, Calif., Oct. 3, 2013 /PRNewswire/ --People who are living with a
rare and serious bleeding disorder will now have one-stop access to
educational resources, financial support, and community connection programs
through CSL Behring's MySource™ program. Launched during the National
Hemophilia Foundation's (NHF) 65^th Annual Meeting, MySource allows patients,
caregivers and healthcare professionals to quickly and easily access CSL
Behring's patient-support resources at one online location www.MySourceCSL.com
or with a one-on-one care coordinator (at 1-800-676-4266).

(Logo: http://photos.prnewswire.com/prnh/20130627/NY39350LOGO )

"CSL Behring has a broad portfolio of coagulation products, a long history of
advancing coagulation therapy, and a thorough understanding of the challenges
facing the bleeding disorders community," said Lynne Powell, Senior Vice
President, North America Commercial Operations, CSL Behring. "We are committed
to providing treatments and supportive services, like MySource, that make a
meaningful difference in the lives of people with bleeding disorders and those
who care for them. We are proud to launch the program during NHF's annual

CSL Behring created MySource to provide members of the bleeding disorders
community with a single source of information that will enhance their
treatment experience. MySource is also designed to meet the specific needs
and preferences of each patient by providing customized information each time
they visit. MySource offers:

  oEducation opportunities that provide members of the bleeding disorders
    community with information about hemophilia and von Willebrand disease
  oFinancial support programs to help ensure individuals are able to access
    their treatment
  oCommunity connections that allow members of the bleeding disorders
    community to share experiences with one another, both online and in person

"For those living with a bleeding disorder, it can be difficult to find a
central location for information about their condition. It can also be
difficult to connect with a community for help in navigating the challenges
associated with a bleeding disorder," said Timothy Grams, who lives with
severe hemophilia A. "The new MySource resource is a welcome addition to
address this need. The site provides a wealth of information for patients and
caregivers alike who are looking to learn more about the condition that
affects them or to connect with others who share similar experiences and

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn. CSL Behring operates one of the world's largest
plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL
Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne,
Australia. For more information, visit www.cslbehring.com.

Media Contact:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring

Madeleine Desmond
Weber Shandwick


Website: http://www.MySourceCSL.com
Website: http://www.cslbehring.com
Press spacebar to pause and continue. Press esc to stop.